Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review

Clinical Pharmacokinetics

Volumn 57, Issue 1, 2018, Pages 7-19

  Stage, Tore B ^a,b   Bergmann, Troels K ^c,d   Kroetz, Deanna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Hospital of South West Jutland   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREMOPHOR; NANOPARTICLE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; GLYCEROL; SURFACTANT;

DATA MINING; DOSE RESPONSE; DRUG CLEARANCE; DRUG FORMULATION; DRUG INFUSION; HUMAN; MAXIMUM CONCENTRATION; MONOTHERAPY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; CHEMISTRY; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASM; NONLINEAR SYSTEM; PATHOLOGY; TIME FACTOR;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCEROL; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; NONLINEAR DYNAMICS; PACLITAXEL; SURFACE-ACTIVE AGENTS; TIME FACTORS;

EID: 85020746663     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-017-0563-z     Document Type: Review

References (115)

1. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999;17:2355–64.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3194–200.
3. Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res. 2004;10:4210s–4s.
4. Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014;6:229ra43.
5. Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem. 1992;35:145–51.
6. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos. 2002;30:438–45.
7. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, et al. Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro and in vivo. J Clin Invest. 2002;110:1309–18.
8. Woo JS, Lee CH, Shim CK, Hwang S-J. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res. 2003;20:24–30.
9. Brooks TA, Minderman H, O’Loughlin KL, Pera P, Ojima I, Baer MR, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003;2:1195–205.
10. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116:824–9.
11. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006;12:6125–32.
12. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005;4:815–8.
13. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther. 2007;81:76–82.
14. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005;57:573–8.
15. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584–90.
16. Harmsen S, Meijerman I, Beijnen JH, Schellens JHM. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009;64:35–43.
17. Kostrubsky VE, Lewis LD, Strom SC, Wood SG, Schuetz EG, Schuetz JD, et al. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys. 1998;355:131–6.
18. Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001;7:3942–9.
19. Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res. 2010;16:2656–65.
20. Hotta K, Ueoka H, Kiura K, Tabata M, Kuyama S, Satoh K, et al. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2004;45:77–84.
21. Leyland-Jones B, Gelmon K, Ayoub J-P, Arnold A, Verma S, Dias R, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21:3965–71.
22. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European–Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–66.
23. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs. 1998;9:1–17.
24. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. Cancer Res. 1999;59:1454–7.
25. Brouwer E, Verweij J, Bruijn PD, Loos WJ, Pillay M, Buijs D, et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos. 2000;28:1141–5.
26. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
27. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.
28. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991;9:1692–703.
29. Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15:317–29.
30. ® (paclitaxel) injection. Princeton: Bristol-Myers Squibb Company. 2011.
31. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125:767–74.
32. Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenom J. 2011;11:113–20.
33. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008;65:767–74.
34. Apellániz-Ruiz M, Lee M-Y, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res. 2015;21:322–8.
35. Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. 2015;21:5082–91.
36. Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman JT, Brosen K. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. Br J Clin Pharmacol. 2016;81:313–5.
37. Shinoda Y, Kimura M, Usami E, Asano H, Yoshimura T. Potential drug interaction between paclitaxel and clopidogrel. Biomed Rep. 2016;5:141–5.
38. Agergaard K, Mau-Sørensen M, Stage TB, Jørgensen TL, Hassel RE, Steffensen KD, et al. Clopidogrel paclitaxel drug–drug interaction: a pharmacoepidemiologic study. Clin Pharmacol Ther. 2017;. doi:10.1002/cpt.674 (Epub 2017 Feb 22).
39. Mielke S, Sparreboom A, Behringer D, Mross K. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res. 2005;25:4423–7.
40. Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res. 2007;13:6410–8.
41. Taxol prescribing information. Princeton: Bristol-Myers Squibb; 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf. Accessed 4 Feb 2017.
42. de Graan A-JM, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res. 2013;19:3316–24.
43. Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016;27:1895–902.
44. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005;11:4843–50.
45. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet. 1994;27:256–69.
46. Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, et al. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Cancer. 2015;121:1817–26.
47. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003;97:2480–6.
48. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, et al. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005;104:1418–27.
49. Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, et al. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol. 2012;69:457–65.
50. Berg SL, Tolcher A, O’Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol. 1995;13:2039–42.
51. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991;9:1261–7.
52. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003;90:610–8.
53. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer. 2001;91:417–22.
54. Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC, Spence AM, et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol. 1998;16:2188–94.
55. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78:34–9.
56. Chen Y, Pandya KJ, Feins R, Johnstone DW, Watson T, Smudzin T, et al. Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71:407–13.
57. Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005;23:311–5.
58. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol. 2001;19:832–42.
59. Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, et al. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2015;33:691–9.
60. Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001;7:3942–9.
61. Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol. 1996;14:774–82.
62. Garcia AA, Keren-Rosenberg S, Parimoo D, Rogers M, Jeffers S, Koda R, et al. Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors. J Clin Oncol. 1998;16:2959–63.
63. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14:4200–5.
64. Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002;8:1237–41.
65. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol. 2002;20:574–81.
66. Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Distribution of paclitaxel in plasma and cerebrospinal fluid. Anticancer Drugs. 2003;14:365–8.
67. Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Lacatelli A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180–90.
68. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol. 2002;20:4440–7.
69. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, et al. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50:788–92.
70. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127–35.
71. Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I, Pinedo HM, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol. 1995;6:699–704.
72. Hurria A, Blanchard MS, Synold TW, Mortimer J, Chung CT, Luu T, et al. Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist. 2015;20:37–44.
73. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038–44.
74. Juan O, Rocher A, Sánchez A, Sánchez JJ, Alberola V. Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose paclitaxel. Chemotherapy. 2005;51:200–5.
75. Kendra KL, Plummer R, Salgia R, O’Brien MER, Paul EM, Suttle AB, et al. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015;14:461–9.
76. Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, et al. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. Semin Oncol. 1997;24:19-16–9.
77. Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, et al. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer. 2012;107:1268–76.
78. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin’s lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs. 1998;9:135–40.
79. Minami H, Sasaki Y, Watanabe T, Ogawa M. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel. Jpn J Cancer Res. 2001;92:231–8.
80. Mross K, Häring B, Holländer N, Mielke S, Behringer D, Massing U, et al. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial. Onkologie. 2002;25:503–8.
81. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995;1:599–606.
82. Panday VR, ten Bokkel Huinink WW, Vermorken JB, Rosing H, Koopman FJ, Swart M, et al. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol Res. 1999;40:67–74.
83. −2 paclitaxel in platinum pretreated patients with advanced ovarian cancer. Pharmacol Res. 1998;38:231–6.
84. 2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol. 2001;47:45–50.
85. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994;12:241–8.
86. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res. 1996;2:941–5.
87. Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol. 2003;21:197–202.
88. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res. 2005;11:4136–43.
89. Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Res. 2002;22:1833–8.
90. Tamura T, Sasaki Y, Eguchi K, Shinkai T, Ohe Y, Nishio M, et al. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res. 1994;85:1057–62.
91. ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A. Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest New Drugs. 2003;21:291–8.
92. Terwogt JMM, Malingré MM, Beijnen JH, ten Huinink Bokkel WW, Rosing H, Koopman FJ, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999;5:3379–84.
93. Toppmeyer DL, Gounder M, Much J, Musanti R, Vyas V, Medina M, et al. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Med Sci Monit. 2003;9:PI99-104.
94. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994;12:1621–9.
95. Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol. 2010;40:404–11.
96. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol. 2001;47:309–18.
97. Hempel G, Rübe C, Mosler C, Wienstroer M, Wagner-Bohn A, Schuck A, et al. Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. Anticancer Drugs. 2003;14:417–22.
98. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005;11:8097–104.
99. Joerger M, Huitema ADR, Huizing MT, Willemse PHB, de Graeff A, Rosing H, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2007;64:622–33.
100. Li Y, Chen N, Palmisano M, Zhou S. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations. Mol Pharm. 2015;12:1308–17.
101. Henningsson A, Sparreboom A, Sandström M, Freijs A, Larsson R, Bergh J, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer. 1990;2003(39):1105–14.
102. van Tellingen O, Huizing MT, Panday VRN, Schellens JHM, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81:330–5.
103. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos. 2011;39:1977–86.
104. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther. 2012;91:846–55.
105. Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009;104:130–7.
106. Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, et al. Phase I and Pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999;5:1723–30.
107. de Jongh FE, de Wit R, Verweij J, Sparreboom A, van den Bent MJ, Stoter G, et al. Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer. 2002;38:2005–13.
108. Kurata T, Tamura T, Shinkai T, Ohe Y, Kunitoh H, Kodama T, et al. Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. Jpn J Clin Oncol. 2001;31:93–9.
109. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:676–84.
110. Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol. 1995;22:91–100.
111. Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, et al. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol. 1997;15:1953–64.
112. Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, et al. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol. 2001;48:333–7.
113. Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol. 2001;12:1067–73.
114. Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab Dispos. 2016;44:1364–71.
115. Wozniak KM, Vornov JJ, Wu Y, Nomoto K, Littlefield BA, DesJardins C, et al. Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity. Cancer Res. 2016;76:3332–9.